AstraZeneca receives FDA approval for new hypertension medication

AstraZeneca announced that the U.S. Food and Drug Administration has approved its hypertension drug, marking a regulatory milestone for the company.

The approval adds to AstraZeneca's cardiovascular portfolio and provides an additional treatment option for patients with high blood pressure.

The development is reported alongside broader industry conversations about China's growing influence in drug development and recent leadership changes at the FDA's CBER and CDER divisions.